KR20080048550A - 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도 - Google Patents
인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도 Download PDFInfo
- Publication number
- KR20080048550A KR20080048550A KR1020087009574A KR20087009574A KR20080048550A KR 20080048550 A KR20080048550 A KR 20080048550A KR 1020087009574 A KR1020087009574 A KR 1020087009574A KR 20087009574 A KR20087009574 A KR 20087009574A KR 20080048550 A KR20080048550 A KR 20080048550A
- Authority
- KR
- South Korea
- Prior art keywords
- carbon atoms
- alkyl
- azabicyclo
- oct
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 title abstract description 12
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title abstract description 7
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 title description 6
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 4
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 title 1
- YJMPFOXUBAJFFA-UHFFFAOYSA-N [1,2]thiazolo[4,3-b]pyridine Chemical compound C1=CC=NC2=CSN=C21 YJMPFOXUBAJFFA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 307
- 238000000034 method Methods 0.000 claims abstract description 155
- 239000000203 mixture Substances 0.000 claims abstract description 57
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims abstract description 42
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 201000010099 disease Diseases 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 208000024891 symptom Diseases 0.000 claims abstract description 13
- 230000004064 dysfunction Effects 0.000 claims abstract description 10
- 230000004913 activation Effects 0.000 claims abstract description 9
- 230000007812 deficiency Effects 0.000 claims abstract description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 1567
- 125000000217 alkyl group Chemical group 0.000 claims description 598
- -1 NH 2 Chemical group 0.000 claims description 309
- 125000003545 alkoxy group Chemical group 0.000 claims description 186
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 138
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 121
- 125000003342 alkenyl group Chemical group 0.000 claims description 108
- 125000000304 alkynyl group Chemical group 0.000 claims description 104
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 104
- 150000003839 salts Chemical class 0.000 claims description 101
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 97
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 95
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims description 93
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 72
- 125000004414 alkyl thio group Chemical group 0.000 claims description 60
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims description 59
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 58
- 239000012453 solvate Substances 0.000 claims description 56
- 239000012458 free base Substances 0.000 claims description 55
- 229910052760 oxygen Inorganic materials 0.000 claims description 54
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 52
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 51
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 50
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 47
- 229910052736 halogen Inorganic materials 0.000 claims description 47
- 229910052731 fluorine Inorganic materials 0.000 claims description 46
- 150000002367 halogens Chemical class 0.000 claims description 46
- 125000003118 aryl group Chemical group 0.000 claims description 45
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 43
- 229920006395 saturated elastomer Polymers 0.000 claims description 43
- 125000001424 substituent group Chemical group 0.000 claims description 43
- 229910052801 chlorine Inorganic materials 0.000 claims description 42
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 38
- 230000036961 partial effect Effects 0.000 claims description 38
- 125000006413 ring segment Chemical group 0.000 claims description 38
- 229910052794 bromium Inorganic materials 0.000 claims description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 37
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims description 36
- 229910052740 iodine Inorganic materials 0.000 claims description 36
- 102000005962 receptors Human genes 0.000 claims description 35
- 108020003175 receptors Proteins 0.000 claims description 35
- 150000001204 N-oxides Chemical class 0.000 claims description 33
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 28
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 27
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 26
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 24
- 125000002252 acyl group Chemical group 0.000 claims description 22
- 125000004423 acyloxy group Chemical group 0.000 claims description 22
- 125000003282 alkyl amino group Chemical group 0.000 claims description 21
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 20
- 206010012289 Dementia Diseases 0.000 claims description 19
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 19
- 125000004434 sulfur atom Chemical group 0.000 claims description 19
- 208000010877 cognitive disease Diseases 0.000 claims description 18
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 18
- 206010027175 memory impairment Diseases 0.000 claims description 17
- 125000004043 oxo group Chemical group O=* 0.000 claims description 17
- 125000004429 atom Chemical group 0.000 claims description 15
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 14
- 208000028698 Cognitive impairment Diseases 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 13
- 208000000044 Amnesia Diseases 0.000 claims description 13
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
- 208000026139 Memory disease Diseases 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 11
- 230000006984 memory degeneration Effects 0.000 claims description 11
- 208000023060 memory loss Diseases 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 239000000556 agonist Substances 0.000 claims description 10
- 229910052786 argon Inorganic materials 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 125000005110 aryl thio group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- 125000002837 carbocyclic group Chemical group 0.000 claims description 7
- 230000001713 cholinergic effect Effects 0.000 claims description 7
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 230000015654 memory Effects 0.000 claims description 7
- 229960002715 nicotine Drugs 0.000 claims description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 210000002569 neuron Anatomy 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- LLSRLLPHUVVLQJ-UHFFFAOYSA-N 1-cycloheptyldiazepane Chemical group C1CCCCCC1N1NCCCCC1 LLSRLLPHUVVLQJ-UHFFFAOYSA-N 0.000 claims description 5
- DNAZCSLXJXKFSN-VJIKYCBLSA-N 5-hydroxy-n-[(3s)-1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-3-carboxamide;iodide Chemical compound [I-].C1=C(O)C=C2C(C(=O)N[C@H]3C4CC[N+](CC4)(C3)C)=NSC2=C1 DNAZCSLXJXKFSN-VJIKYCBLSA-N 0.000 claims description 5
- JLIHVNUIYBYZPX-LLVKDONJSA-N N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-4-hydroxy-1H-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NNC2=C1C(O)=CC=C2 JLIHVNUIYBYZPX-LLVKDONJSA-N 0.000 claims description 5
- ACFJWUDIYCFUQS-SNVBAGLBSA-N N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5,7-dibromo-4-hydroxy-2H-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NNC2=C1C(O)=C(Br)C=C2Br ACFJWUDIYCFUQS-SNVBAGLBSA-N 0.000 claims description 5
- VVFPTCPKNDXWBF-LLVKDONJSA-N N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-bromo-4-hydroxy-1H-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NNC2=C1C(O)=C(Br)C=C2 VVFPTCPKNDXWBF-LLVKDONJSA-N 0.000 claims description 5
- GLTWIURZTPMBTA-GFCCVEGCSA-N N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-hydroxy-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(O)=CC=C21 GLTWIURZTPMBTA-GFCCVEGCSA-N 0.000 claims description 5
- 201000004810 Vascular dementia Diseases 0.000 claims description 5
- 230000007000 age related cognitive decline Effects 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 5
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 claims description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 5
- LJEXBQWZLZFSSN-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-methoxyindazole-3-carboxamide Chemical compound C12=CC=C(OC)C=C2N(CC)N=C1C(=O)N[C@@H]1C(CC2)CCN2C1 LJEXBQWZLZFSSN-HNNXBMFYSA-N 0.000 claims description 5
- NBLLSKMFNOYWGA-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-(difluoromethoxy)-n-methyl-1h-indazole-3-carboxamide Chemical compound C1=C(OC(F)F)C=C2C(C(=O)N([C@@H]3C4CCN(CC4)C3)C)=NNC2=C1 NBLLSKMFNOYWGA-AWEZNQCLSA-N 0.000 claims description 5
- CDIIRPQKBBSHHC-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-methoxy-n-methyl-1h-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1N(C)C(=O)C1=NNC2=CC=C(OC)C=C21 CDIIRPQKBBSHHC-HNNXBMFYSA-N 0.000 claims description 5
- MKPGOIZSZGGKGK-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(difluoromethoxy)-n-methyl-1h-indazole-3-carboxamide Chemical compound FC(F)OC1=CC=C2C(C(=O)N([C@@H]3C4CCN(CC4)C3)C)=NNC2=C1 MKPGOIZSZGGKGK-AWEZNQCLSA-N 0.000 claims description 5
- NCJUWMDMIHBGSN-AWEZNQCLSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-n-methyl-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1N(C)C(=O)C1=NSC2=CC(OC)=CC=C21 NCJUWMDMIHBGSN-AWEZNQCLSA-N 0.000 claims description 5
- GETRXZCCCNYYIV-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-n-methyl-1h-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1N(C)C(=O)C1=NNC2=CC(OC)=CC=C21 GETRXZCCCNYYIV-HNNXBMFYSA-N 0.000 claims description 5
- RDSODELYJDFMBF-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-5-(oxan-4-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=C2)=NNC1=CC=C2C1CCOCC1 RDSODELYJDFMBF-IBGZPJMESA-N 0.000 claims description 5
- YMWLIMACGUHANC-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-6-(1,3-thiazol-2-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2C1=NC=CS1 YMWLIMACGUHANC-INIZCTEOSA-N 0.000 claims description 5
- WQLZMRXMTRRRQR-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-6-(oxan-4-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2C1CCOCC1 WQLZMRXMTRRRQR-IBGZPJMESA-N 0.000 claims description 5
- KPKFCXSWRVNEBQ-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-(cyclopropylmethyl)-6-(1,3-oxazol-2-yl)indazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=C(C=C11)C=2OC=CN=2)=NN1CC1CC1 KPKFCXSWRVNEBQ-GOSISDBHSA-N 0.000 claims description 5
- YLWNWPRABKNCGA-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-(difluoromethyl)-6-(1,3-thiazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(C(F)F)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CS1 YLWNWPRABKNCGA-CQSZACIVSA-N 0.000 claims description 5
- PGEHQXWFCPTXLO-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-(difluoromethyl)-6-(propylcarbamoylamino)indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NN(C(F)F)C2=CC(NC(=O)NCCC)=CC=C21 PGEHQXWFCPTXLO-OAHLLOKOSA-N 0.000 claims description 5
- VQDFGMVDXFKJGX-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-(difluoromethyl)-6-methoxyindazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NN(C(F)F)C2=CC(OC)=CC=C21 VQDFGMVDXFKJGX-CYBMUJFWSA-N 0.000 claims description 5
- SMJVOFILIBVERT-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-cyclopropyl-6-(propylcarbamoylamino)indazole-3-carboxamide Chemical compound C12=CC(NC(=O)NCCC)=CC=C2C(C(=O)N[C@H]2C3CCN(CC3)C2)=NN1C1CC1 SMJVOFILIBVERT-GOSISDBHSA-N 0.000 claims description 5
- DLARADLKNHHUJE-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-(1,3-oxazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(CC)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CO1 DLARADLKNHHUJE-MRXNPFEDSA-N 0.000 claims description 5
- MMPSJJWTNKNLSB-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-(2-oxopyrrolidin-1-yl)indazole-3-carboxamide Chemical compound C1=C2N(CC)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1N1CCCC1=O MMPSJJWTNKNLSB-QGZVFWFLSA-N 0.000 claims description 5
- LJEXBQWZLZFSSN-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-methoxyindazole-3-carboxamide Chemical compound C12=CC=C(OC)C=C2N(CC)N=C1C(=O)N[C@H]1C(CC2)CCN2C1 LJEXBQWZLZFSSN-OAHLLOKOSA-N 0.000 claims description 5
- AOPGWWFRFLXWRH-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-n-methyl-6-(1,3-oxazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(CC)N=C(C(=O)N(C)[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CO1 AOPGWWFRFLXWRH-GOSISDBHSA-N 0.000 claims description 5
- AVAQAIXJHLFBQM-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-methyl-6-(propylcarbamoylamino)indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NN(C)C2=CC(NC(=O)NCCC)=CC=C21 AVAQAIXJHLFBQM-MRXNPFEDSA-N 0.000 claims description 5
- IKXVBFQRYVFHDF-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-propan-2-yl-6-(1,3-thiazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(C(C)C)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CS1 IKXVBFQRYVFHDF-QGZVFWFLSA-N 0.000 claims description 5
- XHLPSFUPKCQDKE-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-propyl-6-(1,3-thiazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(CCC)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CS1 XHLPSFUPKCQDKE-QGZVFWFLSA-N 0.000 claims description 5
- KALULFQIHKKFCX-CYBMUJFWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5,6-dimethoxy-1h-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NNC2=C1C=C(OC)C(OC)=C2 KALULFQIHKKFCX-CYBMUJFWSA-N 0.000 claims description 5
- NBLLSKMFNOYWGA-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-(difluoromethoxy)-n-methyl-1h-indazole-3-carboxamide Chemical compound C1=C(OC(F)F)C=C2C(C(=O)N([C@H]3C4CCN(CC4)C3)C)=NNC2=C1 NBLLSKMFNOYWGA-CQSZACIVSA-N 0.000 claims description 5
- JXJCOTSOYYIMTK-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-hydroxy-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC=C(O)C=C21 JXJCOTSOYYIMTK-GFCCVEGCSA-N 0.000 claims description 5
- CDIIRPQKBBSHHC-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-methoxy-n-methyl-1h-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1N(C)C(=O)C1=NNC2=CC=C(OC)C=C21 CDIIRPQKBBSHHC-OAHLLOKOSA-N 0.000 claims description 5
- MRWSLRJLSYNXEP-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,3-oxazol-2-yl)-1-propylindazole-3-carboxamide Chemical compound C1=C2N(CCC)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CO1 MRWSLRJLSYNXEP-QGZVFWFLSA-N 0.000 claims description 5
- KJGZTJYVDPCJFK-KPMSDPLLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-methylpyrrolidin-3-yl)oxy-1h-indazole-3-carboxamide Chemical compound C1N(C)CCC1OC1=CC=C(C(=NN2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 KJGZTJYVDPCJFK-KPMSDPLLSA-N 0.000 claims description 5
- QANNTZCRFNSNGO-OMOCHNIRSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-OMOCHNIRSA-N 0.000 claims description 5
- INXSFZUBPUKBAA-PKESZJFOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide;hydrochloride Chemical compound Cl.C1C(OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 INXSFZUBPUKBAA-PKESZJFOSA-N 0.000 claims description 5
- VNYHRDSBGYDAQL-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(cyclopropanecarbonylamino)-1-cyclopropylindazole-3-carboxamide Chemical compound C1CC1C(=O)NC(C=C12)=CC=C1C(C(=O)N[C@H]1C3CCN(CC3)C1)=NN2C1CC1 VNYHRDSBGYDAQL-GOSISDBHSA-N 0.000 claims description 5
- MKPGOIZSZGGKGK-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(difluoromethoxy)-n-methyl-1h-indazole-3-carboxamide Chemical compound FC(F)OC1=CC=C2C(C(=O)N([C@H]3C4CCN(CC4)C3)C)=NNC2=C1 MKPGOIZSZGGKGK-CQSZACIVSA-N 0.000 claims description 5
- LJRMDUSLDCDSLB-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(furan-3-ylmethoxy)-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2OCC=1C=COC=1 LJRMDUSLDCDSLB-QGZVFWFLSA-N 0.000 claims description 5
- RTYNUJYXOCMKNQ-FBMWCMRBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(oxolan-3-yloxy)-1h-indazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2OC1CCOC1 RTYNUJYXOCMKNQ-FBMWCMRBSA-N 0.000 claims description 5
- KLZPBWMVYPLJDM-XJKSGUPXSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(4s)-4-hydroxy-2-oxopyrrolidin-1-yl]-1h-indazole-3-carboxamide Chemical compound O=C1C[C@H](O)CN1C1=CC=C(C(=NN2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 KLZPBWMVYPLJDM-XJKSGUPXSA-N 0.000 claims description 5
- KNZGHBOYNALEPF-LLVKDONJSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-hydroxy-2h-indazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NNC2=C1C=CC=C2O KNZGHBOYNALEPF-LLVKDONJSA-N 0.000 claims description 5
- RDSODELYJDFMBF-LJQANCHMSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-5-(oxan-4-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@H]1C2CCN(CC2)C1)C(=O)C(C1=C2)=NNC1=CC=C2C1CCOCC1 RDSODELYJDFMBF-LJQANCHMSA-N 0.000 claims description 5
- VHMKMIXTXOLLSO-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-6-(1,3-oxazol-2-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2C1=NC=CO1 VHMKMIXTXOLLSO-MRXNPFEDSA-N 0.000 claims description 5
- YMWLIMACGUHANC-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-6-(1,3-thiazol-2-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2C1=NC=CS1 YMWLIMACGUHANC-MRXNPFEDSA-N 0.000 claims description 5
- WQLZMRXMTRRRQR-LJQANCHMSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-n-methyl-6-(oxan-4-yl)-1h-indazole-3-carboxamide Chemical compound CN([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2C1CCOCC1 WQLZMRXMTRRRQR-LJQANCHMSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 5
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 206010019196 Head injury Diseases 0.000 claims description 4
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 4
- 206010029350 Neurotoxicity Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 4
- 230000003551 muscarinic effect Effects 0.000 claims description 4
- OMIAFJAGVHVDCS-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-cyclopropyl-6-(1,3-thiazol-2-yl)indazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=C(C=C11)C=2SC=CN=2)=NN1C1CC1 OMIAFJAGVHVDCS-QGZVFWFLSA-N 0.000 claims description 4
- HCHKVJNYNKHIGB-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,3-thiazol-2-yl)-1-thiophen-3-ylindazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=C(C=C11)C=2SC=CN=2)=NN1C=1C=CSC=1 HCHKVJNYNKHIGB-GOSISDBHSA-N 0.000 claims description 4
- 230000004112 neuroprotection Effects 0.000 claims description 4
- 230000007135 neurotoxicity Effects 0.000 claims description 4
- 231100000228 neurotoxicity Toxicity 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 4
- DKHMQEOYLYWADD-XSHJRRMESA-N (e)-[[(3s)-1-(chloromethyl)-1-azoniabicyclo[2.2.2]octan-3-yl]amino]-indazol-3-ylidenemethanolate;hydrochloride Chemical compound [Cl-].C1=CC=C2C(C(=O)N[C@H]3C4CC[N+](CC4)(C3)CCl)=NNC2=C1 DKHMQEOYLYWADD-XSHJRRMESA-N 0.000 claims description 3
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- GGTBELZDHKHESR-UHFFFAOYSA-N 2-cycloheptyloxazepane Chemical group C1CCCCCC1N1OCCCCC1 GGTBELZDHKHESR-UHFFFAOYSA-N 0.000 claims description 3
- WHGCUWGMCOHGCK-BTQNPOSSSA-N 3-[[(3s)-1-azabicyclo[2.2.2]octan-3-yl]carbamoyl]-1h-indazole-6-carboxylic acid;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1NC(=O)C1=NNC2=CC(C(=O)O)=CC=C21 WHGCUWGMCOHGCK-BTQNPOSSSA-N 0.000 claims description 3
- LKQIDYAVNNJMBQ-PPSBMQLTSA-N 6-(1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C2CCCNC2CN1C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=NSC2=C1 LKQIDYAVNNJMBQ-PPSBMQLTSA-N 0.000 claims description 3
- LKQIDYAVNNJMBQ-XUJQIHCRSA-N 6-(1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C2CCCNC2CN1C1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NSC2=C1 LKQIDYAVNNJMBQ-XUJQIHCRSA-N 0.000 claims description 3
- OEJKUAYPQOVDOO-NNBQYGFHSA-N 6-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1CN2CCCC2CN1C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=NSC2=C1 OEJKUAYPQOVDOO-NNBQYGFHSA-N 0.000 claims description 3
- OEJKUAYPQOVDOO-WHCXFUJUSA-N 6-(3,4,6,7,8,8a-hexahydro-1h-pyrrolo[1,2-a]pyrazin-2-yl)-n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1CN2CCCC2CN1C1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NSC2=C1 OEJKUAYPQOVDOO-WHCXFUJUSA-N 0.000 claims description 3
- YMDBAZBYRDLPCO-CDJSEDBCSA-N 6-methoxy-n-[(3s)-1-oxido-1-azoniabicyclo[2.2.2]octan-3-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[N+](CC2)([O-])CCC2[C@@H]1NC(=O)C1=NSC2=CC(OC)=CC=C21 YMDBAZBYRDLPCO-CDJSEDBCSA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 206010027951 Mood swings Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000016620 Tourette disease Diseases 0.000 claims description 3
- 208000029650 alcohol withdrawal Diseases 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 230000007278 cognition impairment Effects 0.000 claims description 3
- 208000017004 dementia pugilistica Diseases 0.000 claims description 3
- 238000001784 detoxification Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000002964 excitative effect Effects 0.000 claims description 3
- 229930195712 glutamate Natural products 0.000 claims description 3
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- DLARADLKNHHUJE-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-(1,3-oxazol-2-yl)indazole-3-carboxamide Chemical compound C1=C2N(CC)N=C(C(=O)N[C@@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CO1 DLARADLKNHHUJE-INIZCTEOSA-N 0.000 claims description 3
- PPNSPIJCCHPEIW-WBVHZDCISA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=C(SN=C2C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 PPNSPIJCCHPEIW-WBVHZDCISA-N 0.000 claims description 3
- PPNSPIJCCHPEIW-RDJZCZTQSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-5-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=C(SN=C2C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 PPNSPIJCCHPEIW-RDJZCZTQSA-N 0.000 claims description 3
- AHPNHYFJXZOJDZ-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCN2CCC1CC2 AHPNHYFJXZOJDZ-IBGZPJMESA-N 0.000 claims description 3
- PBHKPYHGXWPPBB-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCCNCC1 PBHKPYHGXWPPBB-KRWDZBQOSA-N 0.000 claims description 3
- OPCOSSJANZPAQC-OYKVQYDMSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2C1OC1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=NSC2=C1 OPCOSSJANZPAQC-OYKVQYDMSA-N 0.000 claims description 3
- UFVCXVYNCMTGHK-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-methyl-4,5-dihydroimidazol-2-yl)-1h-indazole-3-carboxamide Chemical compound CN1CCN=C1C1=CC=C(C(=NN2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 UFVCXVYNCMTGHK-INIZCTEOSA-N 0.000 claims description 3
- ZZERMSWBCKXSJZ-LWKPJOBUSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-methylpyrrolidin-3-yl)oxy-1,2-benzothiazole-3-carboxamide Chemical compound C1N(C)CCC1OC1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 ZZERMSWBCKXSJZ-LWKPJOBUSA-N 0.000 claims description 3
- SERHSHYNJAZWGI-RUINGEJQSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-methylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound CC1CNCCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 SERHSHYNJAZWGI-RUINGEJQSA-N 0.000 claims description 3
- XNSPJZRHCSNVAR-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-oxo-3-propylimidazolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound O=C1N(CCC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 XNSPJZRHCSNVAR-KRWDZBQOSA-N 0.000 claims description 3
- GRUNLFXWKKKXLJ-SFHVURJKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-oxo-3-propylimidazolidin-1-yl)-1h-indazole-3-carboxamide Chemical compound O=C1N(CCC)CCN1C1=CC=C(C(=NN2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 GRUNLFXWKKKXLJ-SFHVURJKSA-N 0.000 claims description 3
- QANNTZCRFNSNGO-LWKPJOBUSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-LWKPJOBUSA-N 0.000 claims description 3
- UPQISKWJVFVKIC-PKHIMPSTSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methoxypyrrolidin-1-yl)-1h-indazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NN2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 UPQISKWJVFVKIC-PKHIMPSTSA-N 0.000 claims description 3
- QWUQHEDELPXYKR-RUINGEJQSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CNC(C)CN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 QWUQHEDELPXYKR-RUINGEJQSA-N 0.000 claims description 3
- ILUNTYBAPOBZGE-HNNXBMFYSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4,5-dihydro-1h-imidazol-2-yl)-1h-indazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2C1=NCCN1 ILUNTYBAPOBZGE-HNNXBMFYSA-N 0.000 claims description 3
- AIEYPFNAZAQGDT-SFHVURJKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methyl-1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 AIEYPFNAZAQGDT-SFHVURJKSA-N 0.000 claims description 3
- IYXVKOKQRMOGQC-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 IYXVKOKQRMOGQC-KRWDZBQOSA-N 0.000 claims description 3
- GPWNPAULGBLLEA-TVPLGVNVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(N3CC4CCC3CN4C)=CC=C21 GPWNPAULGBLLEA-TVPLGVNVSA-N 0.000 claims description 3
- IVYWDRAWLTUMFE-TVPLGVNVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(N3CC4CCC(C3)N4C)=CC=C21 IVYWDRAWLTUMFE-TVPLGVNVSA-N 0.000 claims description 3
- YIPLPZONCABMSW-QRTARXTBSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(N3C[C@]4(NC[C@]3([H])C4)[H])=CC=C21 YIPLPZONCABMSW-QRTARXTBSA-N 0.000 claims description 3
- YASULIPENFCLRY-BJLQDIEVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-2-(cyclopropanecarbonyl)-2,5-diazabicyclo[2.2.1]heptan-5-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C([C@]1(N(C=2C=C3SN=C(C3=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)C[C@@]2(C1)[H])[H])N2C(=O)C1CC1 YASULIPENFCLRY-BJLQDIEVSA-N 0.000 claims description 3
- SDZSKCLXASPEBT-BQFCYCMXSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-5-(2,2,2-trifluoroethyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(N3C[C@]4(N(C[C@]3([H])C4)CC(F)(F)F)[H])=CC=C21 SDZSKCLXASPEBT-BQFCYCMXSA-N 0.000 claims description 3
- DOUKNGQHWNTBGW-BJLQDIEVSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-5-cyclopropyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C([C@]1(N(C=2C=C3SN=C(C3=CC=2)C(=O)N[C@@H]2C3CCN(CC3)C2)C[C@@]2(C1)[H])[H])N2C1CC1 DOUKNGQHWNTBGW-BJLQDIEVSA-N 0.000 claims description 3
- CHHKUKIZVHLZHF-AEFFLSMTSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 CHHKUKIZVHLZHF-AEFFLSMTSA-N 0.000 claims description 3
- MQHHLXJJSOOTSK-ZBFHGGJFSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 MQHHLXJJSOOTSK-ZBFHGGJFSA-N 0.000 claims description 3
- QANNTZCRFNSNGO-WBVHZDCISA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-WBVHZDCISA-N 0.000 claims description 3
- CHHKUKIZVHLZHF-WMZOPIPTSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 CHHKUKIZVHLZHF-WMZOPIPTSA-N 0.000 claims description 3
- MQHHLXJJSOOTSK-HOCLYGCPSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](O)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 MQHHLXJJSOOTSK-HOCLYGCPSA-N 0.000 claims description 3
- QANNTZCRFNSNGO-RDJZCZTQSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-RDJZCZTQSA-N 0.000 claims description 3
- SALPMAXLHRQAPQ-QUENFVSXSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[1-(cyclopropanecarbonyl)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b]pyridin-6-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(CC12)CC1CCCN2C(=O)C1CC1 SALPMAXLHRQAPQ-QUENFVSXSA-N 0.000 claims description 3
- OATHIWRWYYXFQI-ZYZRXSCRSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(cyclopropylmethoxy)pyrrolidin-1-yl]-1h-indazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2N(C1)CCC1OCC1CC1 OATHIWRWYYXFQI-ZYZRXSCRSA-N 0.000 claims description 3
- SEZMMIPOBTXTEA-WMCAAGNKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(dimethylamino)pyrrolidin-1-yl]-2h-pyrazolo[3,4-b]pyridine-3-carboxamide Chemical compound C1C(N(C)C)CCN1C1=CC=C(C(=NN2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=N1 SEZMMIPOBTXTEA-WMCAAGNKSA-N 0.000 claims description 3
- JRLOWLLNQWPBTN-IBYPIGCZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(methoxymethyl)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(COC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 JRLOWLLNQWPBTN-IBYPIGCZSA-N 0.000 claims description 3
- OFFFQICGZLVGEA-JRZJBTRGSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(methylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(NC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 OFFFQICGZLVGEA-JRZJBTRGSA-N 0.000 claims description 3
- KRVDZCIJALCFCD-DAFXYXGESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-[methyl(2,2,2-trifluoroethyl)amino]pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(N(CC(F)(F)F)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 KRVDZCIJALCFCD-DAFXYXGESA-N 0.000 claims description 3
- YWHWECOSJZZXMH-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[4-(cyclopropanecarbonyl)piperazin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(CC1)CCN1C(=O)C1CC1 YWHWECOSJZZXMH-IBGZPJMESA-N 0.000 claims description 3
- GOZVSIAXGOLHQP-IBGZPJMESA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-[4-(dimethylamino)piperidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1CC(N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 GOZVSIAXGOLHQP-IBGZPJMESA-N 0.000 claims description 3
- HSNPCRQDMDXYQW-ZOWNYOTGSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-1,2-benzothiazole-3-carboxamide;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=CC(OC)=CC=C21 HSNPCRQDMDXYQW-ZOWNYOTGSA-N 0.000 claims description 3
- VXPJCAZSXDAAAL-ZDUSSCGKSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-1,2-benzoxazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NOC2=CC(OC)=CC=C21 VXPJCAZSXDAAAL-ZDUSSCGKSA-N 0.000 claims description 3
- OZIYFRRXGPXXDW-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-piperazin-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCNCC1 OZIYFRRXGPXXDW-INIZCTEOSA-N 0.000 claims description 3
- NEHATUZWLDEXIQ-INIZCTEOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-pyrrolidin-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCCC1 NEHATUZWLDEXIQ-INIZCTEOSA-N 0.000 claims description 3
- OPNCHKXTZMMPLE-ZBFHGGJFSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-ZBFHGGJFSA-N 0.000 claims description 3
- PIDKUZOOEPTSPI-RDJZCZTQSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@@H]1C(CC2)CCN2C1 PIDKUZOOEPTSPI-RDJZCZTQSA-N 0.000 claims description 3
- OPNCHKXTZMMPLE-HOCLYGCPSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-HOCLYGCPSA-N 0.000 claims description 3
- SNBVUKVTZTVDTO-WUJWULDRSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-fluoro-6-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1F SNBVUKVTZTVDTO-WUJWULDRSA-N 0.000 claims description 3
- XDPQUPREVRZXNO-NSHDSACASA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-7-fluoro-6-methoxy-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@H]1NC(=O)C1=NSC2=C(F)C(OC)=CC=C21 XDPQUPREVRZXNO-NSHDSACASA-N 0.000 claims description 3
- KRLDSELWMMWNML-PKLMIRHRSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1-ethyl-6-(1,3-oxazol-2-yl)indazole-3-carboxamide;hydrochloride Chemical compound Cl.C1=C2N(CC)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1C1=NC=CO1 KRLDSELWMMWNML-PKLMIRHRSA-N 0.000 claims description 3
- ZGGYIVUEFFUZRX-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrazolo[3,4-c]pyridine-3-carboxamide Chemical compound N1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NNC2=C1 ZGGYIVUEFFUZRX-GFCCVEGCSA-N 0.000 claims description 3
- FADBLXHAAIWCTG-GFCCVEGCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-1h-pyrazolo[4,3-c]pyridine-3-carboxamide Chemical compound C1=NC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NNC2=C1 FADBLXHAAIWCTG-GFCCVEGCSA-N 0.000 claims description 3
- HVKLEJMKAONLIB-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-(4-methyl-1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCCN1C1=CC=C(SN=C2C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 HVKLEJMKAONLIB-GOSISDBHSA-N 0.000 claims description 3
- PPNSPIJCCHPEIW-NVXWUHKLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=C(SN=C2C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 PPNSPIJCCHPEIW-NVXWUHKLSA-N 0.000 claims description 3
- MWLUPRPDUBKWBG-GHTZIAJQSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-[(3s)-3-(cyclopropylmethoxy)pyrrolidin-1-yl]-1h-indazole-3-carboxamide Chemical compound O([C@H]1CCN(C1)C1=CC=C2NN=C(C2=C1)C(N[C@H]1C2CCN(CC2)C1)=O)CC1CC1 MWLUPRPDUBKWBG-GHTZIAJQSA-N 0.000 claims description 3
- SJYNXACLXWOQGW-MAUKXSAKSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-5-[(3s)-3-methoxypyrrolidin-1-yl]-1h-indazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=C(NN=C2C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 SJYNXACLXWOQGW-MAUKXSAKSA-N 0.000 claims description 3
- AHPNHYFJXZOJDZ-LJQANCHMSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCN2CCC1CC2 AHPNHYFJXZOJDZ-LJQANCHMSA-N 0.000 claims description 3
- PBHKPYHGXWPPBB-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCCNCC1 PBHKPYHGXWPPBB-QGZVFWFLSA-N 0.000 claims description 3
- OPCOSSJANZPAQC-MRTLOADZSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-azabicyclo[2.2.2]octan-3-yloxy)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2C1OC1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NSC2=C1 OPCOSSJANZPAQC-MRTLOADZSA-N 0.000 claims description 3
- UFVCXVYNCMTGHK-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-methyl-4,5-dihydroimidazol-2-yl)-1h-indazole-3-carboxamide Chemical compound CN1CCN=C1C1=CC=C(C(=NN2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 UFVCXVYNCMTGHK-MRXNPFEDSA-N 0.000 claims description 3
- ZZERMSWBCKXSJZ-OMOCHNIRSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(1-methylpyrrolidin-3-yl)oxy-1,2-benzothiazole-3-carboxamide Chemical compound C1N(C)CCC1OC1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 ZZERMSWBCKXSJZ-OMOCHNIRSA-N 0.000 claims description 3
- SERHSHYNJAZWGI-LRHAYUFXSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-methylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound CC1CNCCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 SERHSHYNJAZWGI-LRHAYUFXSA-N 0.000 claims description 3
- GRUNLFXWKKKXLJ-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-oxo-3-propylimidazolidin-1-yl)-1h-indazole-3-carboxamide Chemical compound O=C1N(CCC)CCN1C1=CC=C(C(=NN2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 GRUNLFXWKKKXLJ-GOSISDBHSA-N 0.000 claims description 3
- DOFXBGFMCIIQDS-BZSJEYESSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-ethoxypyrrolidin-1-yl)-7-fluoro-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OCC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1F DOFXBGFMCIIQDS-BZSJEYESSA-N 0.000 claims description 3
- WGFXFRVKAYTEOV-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-ethyl-2-oxoimidazolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound O=C1N(CC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 WGFXFRVKAYTEOV-MRXNPFEDSA-N 0.000 claims description 3
- VJGNOXVGSIIBKG-OMOCHNIRSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methoxypyrrolidin-1-yl)-1,2-benzoxazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NO2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 VJGNOXVGSIIBKG-OMOCHNIRSA-N 0.000 claims description 3
- BIBPBHIZDKQIOZ-PVQCJRHBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-methyl-2-oxopyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound O=C1C(C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 BIBPBHIZDKQIOZ-PVQCJRHBSA-N 0.000 claims description 3
- AIEYPFNAZAQGDT-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methyl-1,4-diazepan-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 AIEYPFNAZAQGDT-GOSISDBHSA-N 0.000 claims description 3
- IYXVKOKQRMOGQC-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 IYXVKOKQRMOGQC-QGZVFWFLSA-N 0.000 claims description 3
- XXXHTSQDIORPMB-GOSISDBHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(4-methylpiperazine-1-carbonyl)-1h-indazole-3-carboxamide Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C(=NN2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 XXXHTSQDIORPMB-GOSISDBHSA-N 0.000 claims description 3
- GPWNPAULGBLLEA-FAFZWHIHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(N3CC4CCC3CN4C)=CC=C21 GPWNPAULGBLLEA-FAFZWHIHSA-N 0.000 claims description 3
- IVYWDRAWLTUMFE-FAFZWHIHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(N3CC4CCC(C3)N4C)=CC=C21 IVYWDRAWLTUMFE-FAFZWHIHSA-N 0.000 claims description 3
- YIPLPZONCABMSW-JLJPHGGASA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(N3C[C@]4(NC[C@]3([H])C4)[H])=CC=C21 YIPLPZONCABMSW-JLJPHGGASA-N 0.000 claims description 3
- YASULIPENFCLRY-CMKODMSKSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-2-(cyclopropanecarbonyl)-2,5-diazabicyclo[2.2.1]heptan-5-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C([C@]1(N(C=2C=C3SN=C(C3=CC=2)C(=O)N[C@H]2C3CCN(CC3)C2)C[C@@]2(C1)[H])[H])N2C(=O)C1CC1 YASULIPENFCLRY-CMKODMSKSA-N 0.000 claims description 3
- QWSOZFFRWVKTNH-YQQAZPJKSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(N3C[C@]4(OC[C@]3([H])C4)[H])=CC=C21 QWSOZFFRWVKTNH-YQQAZPJKSA-N 0.000 claims description 3
- DOUKNGQHWNTBGW-CMKODMSKSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(1s,4s)-5-cyclopropyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C([C@]1(N(C=2C=C3SN=C(C3=CC=2)C(=O)N[C@H]2C3CCN(CC3)C2)C[C@@]2(C1)[H])[H])N2C1CC1 DOUKNGQHWNTBGW-CMKODMSKSA-N 0.000 claims description 3
- CHHKUKIZVHLZHF-SJLPKXTDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3r)-3-(dimethylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 CHHKUKIZVHLZHF-SJLPKXTDSA-N 0.000 claims description 3
- MQHHLXJJSOOTSK-GDBMZVCRSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 MQHHLXJJSOOTSK-GDBMZVCRSA-N 0.000 claims description 3
- QANNTZCRFNSNGO-NVXWUHKLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-NVXWUHKLSA-N 0.000 claims description 3
- CHHKUKIZVHLZHF-FUHWJXTLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 CHHKUKIZVHLZHF-FUHWJXTLSA-N 0.000 claims description 3
- MQHHLXJJSOOTSK-GOEBONIOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](O)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 MQHHLXJJSOOTSK-GOEBONIOSA-N 0.000 claims description 3
- QANNTZCRFNSNGO-DOTOQJQBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 QANNTZCRFNSNGO-DOTOQJQBSA-N 0.000 claims description 3
- SALPMAXLHRQAPQ-NFOQDIRWSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[1-(cyclopropanecarbonyl)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b]pyridin-6-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(CC12)CC1CCCN2C(=O)C1CC1 SALPMAXLHRQAPQ-NFOQDIRWSA-N 0.000 claims description 3
- AFFLFHWMOOWDQB-ROPPNANJSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(cyclopropylmethoxy)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(C1)CCC1OCC1CC1 AFFLFHWMOOWDQB-ROPPNANJSA-N 0.000 claims description 3
- QKJMBWFYXTZCSM-BZSJEYESSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(difluoromethoxy)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC(F)F)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 QKJMBWFYXTZCSM-BZSJEYESSA-N 0.000 claims description 3
- SEZMMIPOBTXTEA-BZSJEYESSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(dimethylamino)pyrrolidin-1-yl]-2h-pyrazolo[3,4-b]pyridine-3-carboxamide Chemical compound C1C(N(C)C)CCN1C1=CC=C(C(=NN2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=N1 SEZMMIPOBTXTEA-BZSJEYESSA-N 0.000 claims description 3
- JRLOWLLNQWPBTN-XPKAQORNSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(methoxymethyl)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(COC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 JRLOWLLNQWPBTN-XPKAQORNSA-N 0.000 claims description 3
- OFFFQICGZLVGEA-FBMWCMRBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(methylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(NC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 OFFFQICGZLVGEA-FBMWCMRBSA-N 0.000 claims description 3
- KRVDZCIJALCFCD-UHUGOGIASA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-[methyl(2,2,2-trifluoroethyl)amino]pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1C(N(CC(F)(F)F)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 KRVDZCIJALCFCD-UHUGOGIASA-N 0.000 claims description 3
- YWHWECOSJZZXMH-LJQANCHMSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[4-(cyclopropanecarbonyl)piperazin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N(CC1)CCN1C(=O)C1CC1 YWHWECOSJZZXMH-LJQANCHMSA-N 0.000 claims description 3
- GOZVSIAXGOLHQP-LJQANCHMSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[4-(dimethylamino)piperidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1CC(N(C)C)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 GOZVSIAXGOLHQP-LJQANCHMSA-N 0.000 claims description 3
- QAGHJHKGEQIEOP-SNVBAGLBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-chloro-[1,2]thiazolo[5,4-b]pyridine-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=NC(Cl)=CC=C21 QAGHJHKGEQIEOP-SNVBAGLBSA-N 0.000 claims description 3
- XIYQUORHPQHVQN-CQSZACIVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-cyano-1h-indazole-3-carboxamide Chemical compound N#CC1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NNC2=C1 XIYQUORHPQHVQN-CQSZACIVSA-N 0.000 claims description 3
- HVNVCUMJPZIHBY-SNVBAGLBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-fluoro-2h-pyrazolo[3,4-b]pyridine-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NNC2=NC(F)=CC=C21 HVNVCUMJPZIHBY-SNVBAGLBSA-N 0.000 claims description 3
- CHOAZMBKIMGLCK-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-imidazol-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1C=CN=C1 CHOAZMBKIMGLCK-OAHLLOKOSA-N 0.000 claims description 3
- HSNPCRQDMDXYQW-BTQNPOSSSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-1,2-benzothiazole-3-carboxamide;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=CC(OC)=CC=C21 HSNPCRQDMDXYQW-BTQNPOSSSA-N 0.000 claims description 3
- RAYAZVOIVKZYFJ-LLVKDONJSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-[1,2]thiazolo[5,4-b]pyridine-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=NC(OC)=CC=C21 RAYAZVOIVKZYFJ-LLVKDONJSA-N 0.000 claims description 3
- ACWVOGYINHFSIT-QGZVFWFLSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-phenyl-2h-pyrazolo[3,4-b]pyridine-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=NC=2C1=CC=CC=C1 ACWVOGYINHFSIT-QGZVFWFLSA-N 0.000 claims description 3
- OZIYFRRXGPXXDW-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-piperazin-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCNCC1 OZIYFRRXGPXXDW-MRXNPFEDSA-N 0.000 claims description 3
- QVXODGVLNJLYCN-OAHLLOKOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-pyrazol-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1C=CC=N1 QVXODGVLNJLYCN-OAHLLOKOSA-N 0.000 claims description 3
- NEHATUZWLDEXIQ-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-pyrrolidin-1-yl-1,2-benzothiazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NSC1=CC=2N1CCCC1 NEHATUZWLDEXIQ-MRXNPFEDSA-N 0.000 claims description 3
- OPNCHKXTZMMPLE-BZSJEYESSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-BZSJEYESSA-N 0.000 claims description 3
- JVYMJXLBAWTLFZ-OFQRWUPVSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(1s,4s)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=C1C=CC=C2N1C[C@@]2([H])OC[C@]1([H])C2 JVYMJXLBAWTLFZ-OFQRWUPVSA-N 0.000 claims description 3
- GLTJKJAUUMPZNP-UKRRQHHQSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3r)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 GLTJKJAUUMPZNP-UKRRQHHQSA-N 0.000 claims description 3
- OPNCHKXTZMMPLE-GDBMZVCRSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3r)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@H](OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-GDBMZVCRSA-N 0.000 claims description 3
- GLTJKJAUUMPZNP-DZGCQCFKSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3s)-3-hydroxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](O)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 GLTJKJAUUMPZNP-DZGCQCFKSA-N 0.000 claims description 3
- OPNCHKXTZMMPLE-GOEBONIOSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3s)-3-methoxypyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](OC)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 OPNCHKXTZMMPLE-GOEBONIOSA-N 0.000 claims description 3
- SNBVUKVTZTVDTO-AWKYBWMHSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-fluoro-6-(3-methoxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(OC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1F SNBVUKVTZTVDTO-AWKYBWMHSA-N 0.000 claims description 3
- XDPQUPREVRZXNO-LLVKDONJSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-fluoro-6-methoxy-1,2-benzothiazole-3-carboxamide Chemical compound C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=C(F)C(OC)=CC=C21 XDPQUPREVRZXNO-LLVKDONJSA-N 0.000 claims description 3
- GGWTWAGLQPRLGQ-UTONKHPSSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-methoxy-1,2-benzothiazole-3-carboxamide;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1NC(=O)C1=NSC2=C1C=CC=C2OC GGWTWAGLQPRLGQ-UTONKHPSSA-N 0.000 claims description 3
- JLEZTDHDKSJERM-LLVKDONJSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-[1,2]thiazolo[5,4-b]pyridine-3-carboxamide Chemical compound C1=CC=C2C(C(N[C@H]3C4CCN(CC4)C3)=O)=NSC2=N1 JLEZTDHDKSJERM-LLVKDONJSA-N 0.000 claims description 3
- JVCZTKPKQDRXED-NYGWOBCZSA-N n-[(3s)-1-oxido-1-azoniabicyclo[2.2.2]octan-3-yl]-5-(trifluoromethoxy)-1h-indazole-3-carboxamide Chemical compound C1=C(OC(F)(F)F)C=C2C(C(=O)N[C@H]3C4CC[N+](CC4)(C3)[O-])=NNC2=C1 JVCZTKPKQDRXED-NYGWOBCZSA-N 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000005586 smoking cessation Effects 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 210000000225 synapse Anatomy 0.000 claims description 3
- 230000001988 toxicity Effects 0.000 claims description 3
- 231100000419 toxicity Toxicity 0.000 claims description 3
- PPNCOQHHSGMKGI-UHFFFAOYSA-N 1-cyclononyldiazonane Chemical group C1CCCCCCCC1N1NCCCCCCC1 PPNCOQHHSGMKGI-UHFFFAOYSA-N 0.000 claims description 2
- NFDXQGNDWIPXQL-UHFFFAOYSA-N 1-cyclooctyldiazocane Chemical group C1CCCCCCC1N1NCCCCCC1 NFDXQGNDWIPXQL-UHFFFAOYSA-N 0.000 claims description 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 2
- 102000009346 Adenosine receptors Human genes 0.000 claims description 2
- 108050000203 Adenosine receptors Proteins 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 206010061216 Infarction Diseases 0.000 claims description 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims description 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 229930003827 cannabinoid Natural products 0.000 claims description 2
- 239000003557 cannabinoid Substances 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 238000002695 general anesthesia Methods 0.000 claims description 2
- 230000007954 hypoxia Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000007574 infarction Effects 0.000 claims description 2
- 230000035987 intoxication Effects 0.000 claims description 2
- 231100000566 intoxication Toxicity 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- JLEZTDHDKSJERM-NSHDSACASA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-[1,2]thiazolo[5,4-b]pyridine-3-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=NSC2=N1 JLEZTDHDKSJERM-NSHDSACASA-N 0.000 claims description 2
- GJYQRQQHVVMNQQ-UNTBIKODSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-oxo-3-propylimidazolidin-1-yl)-1,2-benzothiazole-3-carboxamide;hydrochloride Chemical compound Cl.O=C1N(CCC)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 GJYQRQQHVVMNQQ-UNTBIKODSA-N 0.000 claims description 2
- MQHHLXJJSOOTSK-BZSJEYESSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3-hydroxypyrrolidin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1C(O)CCN1C1=CC=C(C(=NS2)C(=O)N[C@H]3C4CCN(CC4)C3)C2=C1 MQHHLXJJSOOTSK-BZSJEYESSA-N 0.000 claims description 2
- LSJTZJHCZCUIPE-BTQNPOSSSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-methoxy-1,2-benzoxazole-3-carboxamide;hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1NC(=O)C1=NOC2=CC(OC)=CC=C21 LSJTZJHCZCUIPE-BTQNPOSSSA-N 0.000 claims description 2
- PIDKUZOOEPTSPI-DOTOQJQBSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-7-[(3s)-3-(dimethylamino)pyrrolidin-1-yl]-1,2-benzothiazole-3-carboxamide Chemical compound C1[C@@H](N(C)C)CCN1C1=CC=CC2=C1SN=C2C(=O)N[C@H]1C(CC2)CCN2C1 PIDKUZOOEPTSPI-DOTOQJQBSA-N 0.000 claims description 2
- 201000003631 narcolepsy Diseases 0.000 claims description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
- 229940076279 serotonin Drugs 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- OATHIWRWYYXFQI-BDPMCISCSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-[3-(cyclopropylmethoxy)pyrrolidin-1-yl]-1h-indazole-3-carboxamide Chemical compound N([C@H]1C2CCN(CC2)C1)C(=O)C(C1=CC=2)=NNC1=CC=2N(C1)CCC1OCC1CC1 OATHIWRWYYXFQI-BDPMCISCSA-N 0.000 claims 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims 1
- DITBWPUMEUDVLU-UHFFFAOYSA-N 1h-indazole-3-carboxamide Chemical compound C1=CC=C2C(C(=O)N)=NNC2=C1 DITBWPUMEUDVLU-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000010340 Sleep Deprivation Diseases 0.000 claims 1
- CMZNVQYMNCNZGH-UHFFFAOYSA-N [1,2]thiazolo[5,4-b]pyridine-3-carboxamide Chemical compound S1N=C(C=2C1=NC=CC=2)C(=O)N CMZNVQYMNCNZGH-UHFFFAOYSA-N 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 150000001602 bicycloalkyls Chemical group 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 229920001577 copolymer Chemical group 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 230000007257 malfunction Effects 0.000 claims 1
- 230000009225 memory damage Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- FJAYSNIBBGLVJG-MRXNPFEDSA-N n-[(3s)-1-azabicyclo[2.2.2]octan-3-yl]-6-(cyclopropanecarbonylamino)-1-methylindazole-3-carboxamide Chemical compound C1=C2N(C)N=C(C(=O)N[C@H]3C4CCN(CC4)C3)C2=CC=C1NC(=O)C1CC1 FJAYSNIBBGLVJG-MRXNPFEDSA-N 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 14
- 210000004556 brain Anatomy 0.000 abstract description 4
- 239000002253 acid Substances 0.000 description 47
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- 241000124008 Mammalia Species 0.000 description 19
- 239000000460 chlorine Substances 0.000 description 19
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 17
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 17
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 16
- 235000019253 formic acid Nutrition 0.000 description 16
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 16
- 150000001408 amides Chemical class 0.000 description 14
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 14
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 13
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 12
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 12
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- UEXCJVNBTNXOEH-UHFFFAOYSA-N phenyl acethylene Natural products C#CC1=CC=CC=C1 UEXCJVNBTNXOEH-UHFFFAOYSA-N 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 150000007513 acids Chemical class 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 description 7
- 235000010290 biphenyl Nutrition 0.000 description 7
- 239000004305 biphenyl Substances 0.000 description 7
- 125000001624 naphthyl group Chemical group 0.000 description 7
- 229940044601 receptor agonist Drugs 0.000 description 7
- 239000000018 receptor agonist Substances 0.000 description 7
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 6
- 239000005977 Ethylene Substances 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000006880 cross-coupling reaction Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 150000003335 secondary amines Chemical class 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000004677 hydrates Chemical class 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- KNYHISBJRQVMAZ-UHFFFAOYSA-N 1h-pyrazolo[3,4-c]pyridine Chemical group N1=CC=C2C=NNC2=C1 KNYHISBJRQVMAZ-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- 238000005804 alkylation reaction Methods 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000006193 diazotization reaction Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000007127 saponification reaction Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000003107 substituted aryl group Chemical group 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 4
- REUAXQZIRFXQML-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-3-amine Chemical class C1CC2C(N)CN1CC2 REUAXQZIRFXQML-UHFFFAOYSA-N 0.000 description 3
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 3
- BXKYFUGAAFLYJL-BXGYHSFXSA-N 3-[(5e)-5-[(2,4-dimethoxyphenyl)methylidene]-3,4-dihydro-2h-pyridin-6-yl]pyridine;dihydrochloride Chemical compound Cl.Cl.COC1=CC(OC)=CC=C1\C=C/1C(C=2C=NC=CC=2)=NCCC\1 BXKYFUGAAFLYJL-BXGYHSFXSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 206010002022 amyloidosis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 3
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 3
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 3
- 238000006114 decarboxylation reaction Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 238000006396 nitration reaction Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000004031 partial agonist Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XHIZRHINKNJTOJ-UHFFFAOYSA-N tert-butyl 6-(4-hydroxyoxan-4-yl)-1h-indazole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC(C)(C)C)=NNC2=CC=1C1(O)CCOCC1 XHIZRHINKNJTOJ-UHFFFAOYSA-N 0.000 description 3
- 229960003688 tropisetron Drugs 0.000 description 3
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- KTORKRBAIRTBCP-UHFFFAOYSA-N 1,2-benzothiazole-3-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=NSC2=C1 KTORKRBAIRTBCP-UHFFFAOYSA-N 0.000 description 2
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 2
- LSNTUFKHTNZVDL-UHFFFAOYSA-N 1-bromo-4-(difluoromethoxy)-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(OC(F)F)=CC=C1Br LSNTUFKHTNZVDL-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- ZNRGQMMCGHDTEI-UHFFFAOYSA-N 1H-indole-3-carboxylic acid (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) ester Chemical compound C1=CC=C2C(C(=O)OC3CC4CCC(C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-UHFFFAOYSA-N 0.000 description 2
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- SZYVPWPBRABKAB-UHFFFAOYSA-N 3-bromo-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(Br)=C1 SZYVPWPBRABKAB-UHFFFAOYSA-N 0.000 description 2
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYJBAFCUNUMCNS-UHFFFAOYSA-N 6-(oxan-4-yl)-1h-indazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NNC2=CC=1C1CCOCC1 YYJBAFCUNUMCNS-UHFFFAOYSA-N 0.000 description 2
- FWQJCLJQWQXNTD-UHFFFAOYSA-N 6-bromo-1,2-benzothiazole-3-carboxylic acid Chemical compound BrC1=CC=C2C(C(=O)O)=NSC2=C1 FWQJCLJQWQXNTD-UHFFFAOYSA-N 0.000 description 2
- TVWVDWCIELUGGY-UHFFFAOYSA-N 6-methoxy-1,2-benzothiazole-3-carboxylic acid Chemical compound COC1=CC=C2C(C(O)=O)=NSC2=C1 TVWVDWCIELUGGY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 208000009829 Lewy Body Disease Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000003935 attention Effects 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 150000001555 benzenes Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- IOCGMLSHRBHNCM-UHFFFAOYSA-N difluoromethoxy(difluoro)methane Chemical compound FC(F)OC(F)F IOCGMLSHRBHNCM-UHFFFAOYSA-N 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 208000021090 palsy Diseases 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000651 prodrug Chemical group 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 229960001367 tartaric acid Drugs 0.000 description 2
- VSLFHIMHDHPVST-UHFFFAOYSA-N tert-butyl 6-bromo-1h-indazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC(C)(C)C)=NNC2=C1 VSLFHIMHDHPVST-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 1
- WRGKKASJBOREMB-UHFFFAOYSA-N 1,4-dibromo-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1Br WRGKKASJBOREMB-UHFFFAOYSA-N 0.000 description 1
- YDEAOXVCOPZFJV-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octane-2-carboxamide;1h-indazole Chemical class C1=CC=C2C=NNC2=C1.C1CN2C(C(=O)N)CC1CC2 YDEAOXVCOPZFJV-UHFFFAOYSA-N 0.000 description 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
- SWPLPOZVPYOCIK-UHFFFAOYSA-N 1-cycloheptylazepan-2-one Chemical group O=C1CCCCCN1C1CCCCCC1 SWPLPOZVPYOCIK-UHFFFAOYSA-N 0.000 description 1
- LQFNZPNXAIRTJN-UHFFFAOYSA-N 1-ethyl-6-methoxyindazole-3-carboxylic acid Chemical compound C1=C(OC)C=C2N(CC)N=C(C(O)=O)C2=C1 LQFNZPNXAIRTJN-UHFFFAOYSA-N 0.000 description 1
- FHNSIBCRGZEQQZ-UHFFFAOYSA-N 1-tert-butyl-6-formylindazole-3-carboxylic acid Chemical compound C1=C(C=O)C=C2N(C(C)(C)C)N=C(C(O)=O)C2=C1 FHNSIBCRGZEQQZ-UHFFFAOYSA-N 0.000 description 1
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical compound C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 description 1
- DLHWKJDYXPNWAI-UHFFFAOYSA-N 2,2,2-trichloro-1-ethoxyethanol Chemical compound CCOC(O)C(Cl)(Cl)Cl DLHWKJDYXPNWAI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- GMVGSGXEYKPCSS-UHFFFAOYSA-N 2-bromo-1-nitro-4-phenylmethoxybenzene Chemical compound C1=C(Br)C([N+](=O)[O-])=CC=C1OCC1=CC=CC=C1 GMVGSGXEYKPCSS-UHFFFAOYSA-N 0.000 description 1
- RXTRRIFWCJEMEL-UHFFFAOYSA-N 2-chloropyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1Cl RXTRRIFWCJEMEL-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- HTKXRTUKPXEALT-UHFFFAOYSA-N 3-bromo-2h-indazole Chemical compound C1=CC=CC2=C(Br)NN=C21 HTKXRTUKPXEALT-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LTWINMJBBFVXGY-UHFFFAOYSA-N 3-methyl-[1,2]thiazolo[5,4-b]pyridine Chemical group C1=CC=C2C(C)=NSC2=N1 LTWINMJBBFVXGY-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JOTRPRKONYTVBV-UHFFFAOYSA-N 4-chloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CN=CC=C1Cl JOTRPRKONYTVBV-UHFFFAOYSA-N 0.000 description 1
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
- RHXWAMSYANZWMS-UHFFFAOYSA-N 4-methoxy-1h-indazole Chemical compound COC1=CC=CC2=C1C=NN2 RHXWAMSYANZWMS-UHFFFAOYSA-N 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 1
- REXPARGQDTXNQS-UHFFFAOYSA-N 5-(difluoromethoxy)-1h-indazole-3-carboxylic acid Chemical compound C1=C(OC(F)F)C=C2C(C(=O)O)=NNC2=C1 REXPARGQDTXNQS-UHFFFAOYSA-N 0.000 description 1
- BBVXRCQSXHSLFG-UHFFFAOYSA-N 5-(oxan-4-yl)-1h-indazole-3-carboxylic acid Chemical compound C1=C2C(C(=O)O)=NNC2=CC=C1C1CCOCC1 BBVXRCQSXHSLFG-UHFFFAOYSA-N 0.000 description 1
- LJSFFGFRQGXQEE-UHFFFAOYSA-N 5-bromo-1,2-benzothiazole-3-carboxylic acid Chemical compound C1=C(Br)C=C2C(C(=O)O)=NSC2=C1 LJSFFGFRQGXQEE-UHFFFAOYSA-N 0.000 description 1
- CGKRYEFLVDXZOX-UHFFFAOYSA-N 6-(3,6-dihydro-2h-pyran-4-yl)-1h-indazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NNC2=CC=1C1=CCOCC1 CGKRYEFLVDXZOX-UHFFFAOYSA-N 0.000 description 1
- BMGQSBRVWYCFLL-UHFFFAOYSA-N 6-bromo-1-ethylindazole-3-carboxylic acid Chemical compound C1=C(Br)C=C2N(CC)N=C(C(O)=O)C2=C1 BMGQSBRVWYCFLL-UHFFFAOYSA-N 0.000 description 1
- OPJAPPYKVWTEQM-UHFFFAOYSA-N 6-bromo-1-methylindazole-3-carboxylic acid Chemical compound C1=C(Br)C=C2N(C)N=C(C(O)=O)C2=C1 OPJAPPYKVWTEQM-UHFFFAOYSA-N 0.000 description 1
- ZOHKZLZEKUEPIR-UHFFFAOYSA-N 6-methoxy-1-benzothiophene-2,3-dione Chemical compound COC1=CC=C2C(=O)C(=O)SC2=C1 ZOHKZLZEKUEPIR-UHFFFAOYSA-N 0.000 description 1
- JBPCEKWXGCHLSX-UHFFFAOYSA-N 6-phenylmethoxy-1h-indazole-3-carboxylic acid Chemical class C=1C=C2C(C(=O)O)=NNC2=CC=1OCC1=CC=CC=C1 JBPCEKWXGCHLSX-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- AZYHMKOKAWRIDH-UHFFFAOYSA-N 7-bromo-1,2-benzothiazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NSC2=C1Br AZYHMKOKAWRIDH-UHFFFAOYSA-N 0.000 description 1
- 229940122656 Alpha-7 nicotinic receptor agonist Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710195183 Alpha-bungarotoxin Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- AUBPMADJYNSPOA-UHFFFAOYSA-N Anabaseine Chemical compound C1CCCC(C=2C=NC=CC=2)=N1 AUBPMADJYNSPOA-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000012184 Diffuse Brain injury Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010073681 Epidural haemorrhage Diseases 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 201000002795 Muckle-Wells syndrome Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 241000244169 Nemertea Species 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 229940123925 Nicotinic receptor agonist Drugs 0.000 description 1
- BNUHAJGCKIQFGE-UHFFFAOYSA-N Nitroanisol Chemical compound COC1=CC=C([N+]([O-])=O)C=C1 BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- 241000237854 Sipunculus nudus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 208000032930 Spastic paraplegia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 206010042364 Subdural haemorrhage Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000032859 Synucleinopathies Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- MNBJEUWONPHKSB-UHFFFAOYSA-N [1,2]thiazolo[5,4-b]pyridine-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NSC2=N1 MNBJEUWONPHKSB-UHFFFAOYSA-N 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 description 1
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- RVSPCRWXESLLJY-UHFFFAOYSA-N azane;1h-indazole Chemical compound N.C1=CC=C2C=NNC2=C1 RVSPCRWXESLLJY-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004517 catalytic hydrocracking Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000025434 cerebellar degeneration Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000007256 debromination reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- GZKHDVAKKLTJPO-UHFFFAOYSA-N ethyl 2,2-difluoroacetate Chemical compound CCOC(=O)C(F)F GZKHDVAKKLTJPO-UHFFFAOYSA-N 0.000 description 1
- GVCAWQUJCHZRCB-UHFFFAOYSA-N ethyl 2-chloro-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Cl GVCAWQUJCHZRCB-UHFFFAOYSA-N 0.000 description 1
- VRZVPALEJCLXPR-UHFFFAOYSA-N ethyl 4-methylbenzenesulfonate Chemical compound CCOS(=O)(=O)C1=CC=C(C)C=C1 VRZVPALEJCLXPR-UHFFFAOYSA-N 0.000 description 1
- LFWBFXSJXLTAIJ-UHFFFAOYSA-N ethyl 5-methoxy-1h-indazole-3-carboxylate Chemical compound C1=C(OC)C=C2C(C(=O)OCC)=NNC2=C1 LFWBFXSJXLTAIJ-UHFFFAOYSA-N 0.000 description 1
- ZMOIGRSGHBJKSS-UHFFFAOYSA-N ethyl 6-bromo-1,2-benzothiazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=NSC2=C1 ZMOIGRSGHBJKSS-UHFFFAOYSA-N 0.000 description 1
- ADEQGMXEHRCMKL-UHFFFAOYSA-N ethyl 6-bromo-1,2-benzoxazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=NOC2=C1 ADEQGMXEHRCMKL-UHFFFAOYSA-N 0.000 description 1
- VSZWWEMXQRFTOM-UHFFFAOYSA-N ethyl 6-methoxy-1,2-benzothiazole-3-carboxylate Chemical compound COC1=CC=C2C(C(=O)OCC)=NSC2=C1 VSZWWEMXQRFTOM-UHFFFAOYSA-N 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- UVECLJDRPFNRRQ-UHFFFAOYSA-N ethyl trifluoromethanesulfonate Chemical compound CCOS(=O)(=O)C(F)(F)F UVECLJDRPFNRRQ-UHFFFAOYSA-N 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001465 metallisation Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- XLTANAWLDBYGFU-VTLKBQQISA-N methyllycaconitine Chemical compound C([C@]12CN([C@@H]3[C@@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@H](C5)OC)C[C@H]6[C@@]3([C@@H]1[C@@H]4OC)[C@@H](OC)CC2)CC)OC(=O)C1=CC=CC=C1N1C(=O)C[C@H](C)C1=O XLTANAWLDBYGFU-VTLKBQQISA-N 0.000 description 1
- XLTANAWLDBYGFU-UHFFFAOYSA-N methyllycaconitine hydrochloride Natural products C1CC(OC)C2(C3C4OC)C5CC(C(C6)OC)C(OC)C5C6(O)C4(O)C2N(CC)CC31COC(=O)C1=CC=CC=C1N1C(=O)CC(C)C1=O XLTANAWLDBYGFU-UHFFFAOYSA-N 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- DCZRWLMGPSDYCR-IBYPIGCZSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]-6-(3,4-dimethylpiperazin-1-yl)-1,2-benzothiazole-3-carboxamide Chemical compound C1CN(C)C(C)CN1C1=CC=C(C(=NS2)C(=O)N[C@@H]3C4CCN(CC4)C3)C2=C1 DCZRWLMGPSDYCR-IBYPIGCZSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- JMJRYTGVHCAYCT-UHFFFAOYSA-N oxan-4-one Chemical compound O=C1CCOCC1 JMJRYTGVHCAYCT-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 208000001282 primary progressive aphasia Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical group C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 150000008584 quinuclidines Chemical class 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- UXAWXZDXVOYLII-UHFFFAOYSA-N tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1C2N(C(=O)OC(C)(C)C)CC1NC2 UXAWXZDXVOYLII-UHFFFAOYSA-N 0.000 description 1
- FJYZXKYGRCRNNP-UHFFFAOYSA-N tert-butyl 5-bromo-1,2-benzothiazole-3-carboxylate Chemical compound C1=C(Br)C=C2C(C(=O)OC(C)(C)C)=NSC2=C1 FJYZXKYGRCRNNP-UHFFFAOYSA-N 0.000 description 1
- ULLIEAKUNMXLAM-UHFFFAOYSA-N tert-butyl 6-bromo-1,2-benzothiazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC(C)(C)C)=NSC2=C1 ULLIEAKUNMXLAM-UHFFFAOYSA-N 0.000 description 1
- OJSDQXGKXGPFPP-UHFFFAOYSA-N tert-butyl 6-formyl-1h-indazole-3-carboxylate Chemical compound O=CC1=CC=C2C(C(=O)OC(C)(C)C)=NNC2=C1 OJSDQXGKXGPFPP-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- LYTCVQQGCSNFJU-LKGYBJPKSA-N α-bungarotoxin Chemical compound C(/[C@H]1O[C@H]2C[C@H]3O[C@@H](CC(=C)C=O)C[C@H](O)[C@]3(C)O[C@@H]2C[C@@H]1O[C@@H]1C2)=C/C[C@]1(C)O[C@H]1[C@@]2(C)O[C@]2(C)CC[C@@H]3O[C@@H]4C[C@]5(C)O[C@@H]6C(C)=CC(=O)O[C@H]6C[C@H]5O[C@H]4C[C@@H](C)[C@H]3O[C@H]2C1 LYTCVQQGCSNFJU-LKGYBJPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71955205P | 2005-09-23 | 2005-09-23 | |
| US60/719,552 | 2005-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20080048550A true KR20080048550A (ko) | 2008-06-02 |
Family
ID=37715973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020087009574A Ceased KR20080048550A (ko) | 2005-09-23 | 2006-09-22 | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1940833A1 (enExample) |
| JP (1) | JP2009509964A (enExample) |
| KR (1) | KR20080048550A (enExample) |
| CN (1) | CN101312968A (enExample) |
| AU (1) | AU2006295397A1 (enExample) |
| BR (1) | BRPI0617534A2 (enExample) |
| CA (1) | CA2622677A1 (enExample) |
| IL (1) | IL190358A0 (enExample) |
| RU (1) | RU2450003C2 (enExample) |
| SG (1) | SG165417A1 (enExample) |
| WO (1) | WO2007038367A1 (enExample) |
| ZA (1) | ZA200802342B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101532211B1 (ko) * | 2014-04-30 | 2015-06-30 | 세종대학교산학협력단 | Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법 |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| KR101280333B1 (ko) | 2006-03-28 | 2013-07-02 | 하이 포인트 파마슈티칼스, 엘엘씨 | 히스타민 ｈ３ 수용체 활성을 갖는 벤조티아졸 |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| MX2010005298A (es) * | 2007-11-16 | 2010-06-30 | Rigel Pharmaceuticals Inc | Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos. |
| BRPI0908807A2 (pt) * | 2008-02-15 | 2015-07-28 | Hoffmann La Roche | Derivados de 3-alquil-piperazina e usos dos mesmos |
| CA2740311C (en) * | 2008-10-13 | 2013-09-17 | F. Hoffmann-La Roche Ag | Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides |
| SI2889033T1 (en) | 2008-11-19 | 2018-08-31 | Forum Pharmaceuticals Inc. | Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| US20110172428A1 (en) | 2010-01-12 | 2011-07-14 | Shan-Ming Kuang | Methods for the preparation of indazole-3-carboxylic acid and n-(s)-1-azabicyclo[2.2.2]oct-3-yl-1h-indazole-3-carboxamide hydrochloride salt |
| US8481555B2 (en) * | 2010-04-30 | 2013-07-09 | Bristol-Myers Squibb Company | Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs |
| CN103221411B (zh) | 2010-05-17 | 2016-05-11 | 富瑞姆制药公司 | (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型 |
| US8242276B2 (en) | 2010-06-30 | 2012-08-14 | Hoffmann-La Roche Inc. | Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt |
| US20130225560A1 (en) | 2010-07-26 | 2013-08-29 | Envivo Pharmaceuticals, Inc. | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors |
| AR086791A1 (es) * | 2011-07-01 | 2014-01-22 | Lundbeck & Co As H | Moduladores alostericos positivos del receptor de acetilcolina nicotinico |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| JOP20130213B1 (ar) | 2012-07-17 | 2021-08-17 | Takeda Pharmaceuticals Co | معارضات لمستقبلht3-5 |
| JOP20130273B1 (ar) * | 2012-09-11 | 2021-08-17 | Genzyme Corp | مثبطات انزيم (سينثاز) غلوكوسيل سيراميد |
| JP6249952B2 (ja) * | 2012-10-16 | 2017-12-20 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2016526538A (ja) | 2013-06-20 | 2016-09-05 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺ダニ剤及び殺虫剤としてのアリールスルフィド誘導体及びアリールスルホキシド誘導体 |
| WO2015018754A1 (en) * | 2013-08-08 | 2015-02-12 | Boehringer Ingelheim International Gmbh | Novel pyrazine amide compounds |
| CA2942687A1 (en) | 2014-03-20 | 2015-09-24 | Samumed, Llc | 5-substituted indazole-3-carboxamides and preparation and use thereof |
| HUE055175T2 (hu) | 2014-09-29 | 2021-11-29 | Takeda Pharmaceuticals Co | Az 1-(1-metil-1H-pirazol-4-il)-N-((1R,5S,7S)-9-metil-3-oxa-9-azabiciklo[3.3.1] nonan-7-il)-1H-indol-3-karboxamid kristályos formája |
| JP2018516973A (ja) * | 2015-06-10 | 2018-06-28 | フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | α７−ニコチン性アセチルコリン受容体のアゴニストとしてのアミノベンゾイソオキサゾール化合物 |
| EP3334740A4 (en) * | 2015-08-12 | 2019-02-06 | Axovant Sciences GmbH | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF ALPHA 7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| CA3251507A1 (en) * | 2015-10-16 | 2025-05-21 | Abbvie Inc | Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis |
| US20200115353A1 (en) | 2017-04-06 | 2020-04-16 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| EP3632908A1 (en) | 2018-10-02 | 2020-04-08 | Inventiva | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
| TW202142236A (zh) | 2020-02-03 | 2021-11-16 | 美商健臻公司 | 用於治療與溶體儲積症相關的神經症狀之方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| AU2021311131A1 (en) | 2020-07-24 | 2023-03-23 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA93737B (en) * | 1992-02-04 | 1993-09-06 | Eisai Co Ltd | Aminobenzoic acid derivatives. |
| AR036040A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen |
| AR036041A1 (es) * | 2001-06-12 | 2004-08-04 | Upjohn Co | Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen |
| DE10162375A1 (de) * | 2001-12-19 | 2003-07-10 | Bayer Ag | Bicyclische N-Aryl-amide |
| PL375533A1 (en) * | 2002-08-14 | 2005-11-28 | Neurosearch A/S | Novel quinuclidine derivatives and their use |
| CA2499128C (en) * | 2002-09-25 | 2012-07-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| EP1587511A2 (en) * | 2003-01-22 | 2005-10-26 | Pharmacia & Upjohn Company LLC | Treatment of diseases with alpha-7 nach receptor full agonists |
| US7396833B2 (en) * | 2003-12-22 | 2008-07-08 | Memory Pharmaceuticals Corporation | Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
-
2006
- 2006-09-22 WO PCT/US2006/037142 patent/WO2007038367A1/en not_active Ceased
- 2006-09-22 BR BRPI0617534-1A patent/BRPI0617534A2/pt not_active IP Right Cessation
- 2006-09-22 JP JP2008532459A patent/JP2009509964A/ja active Pending
- 2006-09-22 RU RU2008115268/04A patent/RU2450003C2/ru not_active IP Right Cessation
- 2006-09-22 AU AU2006295397A patent/AU2006295397A1/en not_active Abandoned
- 2006-09-22 CN CNA2006800439794A patent/CN101312968A/zh active Pending
- 2006-09-22 EP EP06815264A patent/EP1940833A1/en not_active Withdrawn
- 2006-09-22 CA CA002622677A patent/CA2622677A1/en not_active Abandoned
- 2006-09-22 KR KR1020087009574A patent/KR20080048550A/ko not_active Ceased
- 2006-09-22 SG SG201006955-7A patent/SG165417A1/en unknown
-
2008
- 2008-03-12 ZA ZA200802342A patent/ZA200802342B/xx unknown
- 2008-03-20 IL IL190358A patent/IL190358A0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101532211B1 (ko) * | 2014-04-30 | 2015-06-30 | 세종대학교산학협력단 | Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법 |
| WO2015167246A1 (ko) * | 2014-04-30 | 2015-11-05 | 세종대학교 산학협력단 | Ａｍｐｋ 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0617534A2 (pt) | 2011-07-26 |
| CA2622677A1 (en) | 2007-04-05 |
| IL190358A0 (en) | 2009-09-22 |
| SG165417A1 (en) | 2010-10-28 |
| RU2450003C2 (ru) | 2012-05-10 |
| RU2008115268A (ru) | 2009-10-27 |
| CN101312968A (zh) | 2008-11-26 |
| AU2006295397A1 (en) | 2007-04-05 |
| EP1940833A1 (en) | 2008-07-09 |
| ZA200802342B (en) | 2009-03-25 |
| JP2009509964A (ja) | 2009-03-12 |
| WO2007038367A1 (en) | 2007-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080048550A (ko) | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸,피라졸로피리딘, 이소티아졸로피리딘, 및 이들의 제법 및용도 | |
| US8106066B2 (en) | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | |
| KR101176670B1 (ko) | 인다졸, 벤조티아졸, 벤조이소티아졸, 벤즈이속사졸, 및그의 제조법 및 용도 | |
| EP1742944B1 (en) | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof | |
| KR101129933B1 (ko) | 인다졸, 벤조티아졸 및 벤조이소티아졸 및 그의 제조 및용도 | |
| KR20070087674A (ko) | 니코틴 α-７ 수용체 리간드 및 이의 제조 및 용도 | |
| EP1745046B1 (en) | 1 h-indazoles, benzothiazoles, 1,2-benziosoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | |
| KR20060120694A (ko) | 인돌, 1ｈ-인다졸, 1,2-벤즈이속사졸 및1,2-벤즈이소티아졸, 및 이들의 제법 및 용도 | |
| US7932248B2 (en) | 1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof | |
| ES2356251T3 (es) | Indoles, 1h-indazoles, 1,2-bencisoxazoles, 1,2-bencisotiazoles y preparación y usos de los mismos. | |
| HK1122029A (en) | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | |
| CN101124226A (zh) | 1h-吲唑、苯并噻唑、1,2-苯并异噁唑、1,2-苯并异噻唑和色酮以及它们的制备和用途 | |
| HK1112743A (en) | Nicotinic alpha-7 receptor ligands and preparation and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20080422 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20110921 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130501 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20130730 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130501 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |